Futura medical, healthcare company focused on advanced transdermal technology, has announced its preliminary results for the year 2016.
Futura has reported loss of €4,3 million for the year 2016. The company has decreased the loss in comparison to the last year when it reported loss of €5,9 million.
James Barder, Futura’s Chief Executive, commented: “Futura continues to make good progress, both commercially and clinically, across its portfolio of product opportunities and we look forward to the year ahead with confidence. 2017 has started well with the launch in the Middle East of CSD500, our novel erectogenic condom, and the signing of a licensing deal for TPR100, our diclofenac pain relief gel. We have the balance sheet strength to drive forward our exciting clinical plans for MED2002, our breakthrough erectile dysfunction gel, with potential for significant prescription sales, once approved, and the prospect of an over-the-counter switch in the future to enable additional sales.”